Biotech Force Danmark ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  2.3% 3.7% 4.0% 9.7% 13.1%  
Credit score (0-100)  66 52 48 24 17  
Credit rating  BBB BBB BBB BB BB  
Credit limit (kDKK)  0.1 0.0 0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -485 -1,485 -1,879 -2,965 -2,419  
EBITDA  -485 -1,485 -1,879 -2,965 -11,811  
EBIT  -1,032 -2,078 -2,540 -2,965 -11,811  
Pre-tax profit (PTP)  -1,245.7 -2,517.4 -2,909.3 -3,470.9 -12,373.4  
Net earnings  -971.5 -1,931.3 -2,265.5 -2,696.2 -11,723.2  
Pre-tax profit without non-rec. items  -1,246 -2,517 -2,909 -3,471 -12,373  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  20,023 19,539 18,969 0.0 0.0  
Shareholders equity total  5,572 4,640 2,375 -321 -12,044  
Interest-bearing liabilities  13,510 26,858 29,963 14,916 18,683  
Balance sheet total (assets)  21,423 36,177 34,218 17,023 14,143  

Net Debt  13,510 26,858 29,963 14,808 18,549  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -485 -1,485 -1,879 -2,965 -2,419  
Gross profit growth  0.0% -206.1% -26.6% -57.8% 18.4%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  21,423 36,177 34,218 17,023 14,143  
Balance sheet change%  -29.8% 68.9% -5.4% -50.3% -16.9%  
Added value  -485.0 -1,484.6 -1,879.4 -2,304.2 -11,810.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -8,671 -466 -1,322 -14,136 -5,515  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 -3.0 -4.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  212.8% 140.0% 135.2% 100.0% 488.3%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -3.8% -7.2% -7.2% -11.5% -54.0%  
ROI %  -3.8% -7.5% -7.4% -12.0% -56.5%  
ROE %  -16.0% -37.8% -64.6% -27.8% -75.2%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  26.0% 12.8% 6.9% -1.9% -46.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -2,785.5% -1,809.2% -1,594.2% -499.4% -157.1%  
Gearing %  242.5% 578.8% 1,261.6% -4,642.2% -155.1%  
Net interest  0 0 0 0 0  
Financing costs %  2.0% 2.2% 1.3% 2.3% 3.7%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.2 0.4 0.3 0.4 0.2  
Current Ratio  0.2 0.7 0.6 1.0 0.8  
Cash and cash equivalent  0.0 0.0 0.0 108.0 134.6  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -5,531.9 -6,779.7 -9,367.7 199.7 -4,565.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0